Loading...
XASXARX
Market cap146mUSD
Dec 20, Last price  
0.68AUD
1D
-2.16%
1Q
38.78%
IPO
-53.74%
Name

Aroa Biosurgery Ltd

Chart & Performance

D1W1MN
XASX:ARX chart
P/E
P/S
4.05
EPS
Div Yield, %
0.00%
Shrs. gr., 5y
2.76%
Rev. gr., 5y
24.08%
Revenues
63m
+6.83%
9,663,46821,766,08323,826,65920,510,41936,880,75059,309,18263,357,490
Net income
-10m
-1,178,832896,261-5,661,159000-9,748,266
CFO
-7m
-2,804,80701,577,295-4,675,457-10,860,5220-6,764,533
Earnings
Mar 20, 2025

Profile

Aroa Biosurgery Limited, a regenerative medicine company, engages in the developing, manufacturing, and distributing medical devices for wound and tissue repair using extracellular matrix (ECM) technology in the United States and internationally. The company's products include Endoform Natural and Endoform Antimicrobia Restorative Bioscaffold for treating acute and chronic wounds; Myriad Matrix, an engineered ECM for soft tissue repair, reinforcement, and complex wounds; Myriad Morcells, a morcellized (powdered) format of Myriad Matrix for soft tissue repair and complex wounds; and Reinforced Bioscaffolds, a surgical product for use in ventral hernia repair and abdominal wall reconstruction. Aroa Biosurgery Limited was incorporated in 2007 and is headquartered in Auckland, New Zealand.
IPO date
Jul 24, 2020
Employees
6
Domiciled in
NZ
Incorporated in
NZ

Valuation

Title
NZD in thousands, except ratios and share amounts
FYFYFYFYFYFYFY
2024‑032023‑032022‑032021‑032020‑032019‑032018‑03
Income
Revenues
63,357
6.83%
59,309
60.81%
36,881
79.81%
Cost of revenue
75,359
63,844
45,022
Unusual Expense (Income)
NOPBT
(12,001)
(4,535)
(8,141)
NOPBT Margin
Operating Taxes
184
11
116
Tax Rate
NOPAT
(12,186)
(4,546)
(8,257)
Net income
(9,748)
 
Dividends
Dividend yield
Proceeds from repurchase of equity
180
46,774
BB yield
Debt
Debt current
921
523
547
Long-term debt
12,720
12,782
10,375
Deferred revenue
Other long-term liabilities
160
160
152
Net debt
(14,088)
(29,692)
(42,431)
Cash flow
Cash from operating activities
(6,765)
(10,861)
CAPEX
(3,231)
Cash from investing activities
9,309
6,791
Cash from financing activities
(958)
34,978
FCF
(25,629)
(9,797)
(19,674)
Balance
Cash
27,727
42,997
53,354
Long term investments
2
Excess cash
24,561
40,032
51,510
Stockholders' equity
87,104
143,607
140,923
Invested Capital
69,510
62,158
47,458
ROIC
ROCE
EV
Common stock shares outstanding
343,825
342,917
342,162
Price
Market cap
EV
EBITDA
(12,001)
(1,031)
(5,187)
EV/EBITDA
Interest
1,163
697
Interest/NOPBT